Group 1 - The core point of the news is that southbound funds have significantly increased their holdings in MicroPort Scientific Corporation (00853.HK), with a total net increase of 13.18 million shares over the last five trading days and 47.15 million shares over the last twenty trading days [1][2] - As of October 17, 2025, southbound funds hold 876 million shares of MicroPort, accounting for 45.8% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show fluctuations, with a notable increase of 4.95 million shares on October 16, 2025, and a decrease of 519,300 shares on October 15, 2025 [2] Group 2 - MicroPort Scientific Corporation specializes in the manufacturing and sales of medical devices, with divisions focused on orthopedic, cardiovascular, neuro-interventional, surgical, robotic, cardiac rhythm management, and heart valve products [2]

Core Insights - The top three companies with the highest short positions as of October 3 are COSCO Shipping Holdings (01919), Ganfeng Lithium (01772), and ZTE Corporation (00763), with short ratios of 15.66%, 15.25%, and 15.16% respectively [1][2] - Ganfeng Lithium (01772) saw the largest absolute increase in short positions, rising by 1.20%, followed by Minmetals Resources (01208) with an increase of 0.96%, and Yuexiu Transport Infrastructure (01052) with an increase of 0.76% [1][2] - The companies with the largest decreases in short positions include GCL-Poly Energy (03800), which decreased by 3.16%, followed by Dongfang Electric (01072) with a decrease of 2.03%, and Jinxin Fertility (01951) with a decrease of 0.76% [1][3] Summary of Short Positions - **Top 10 Companies by Short Ratio** - COSCO Shipping Holdings (01919): 15.66% (from 437 million shares to 451 million shares) - Ganfeng Lithium (01772): 15.25% (from 62.30 million shares to 67.64 million shares) - ZTE Corporation (00763): 15.16% (from 113 million shares to 115 million shares) - CATL (03750): 13.83% (from 21.12 million shares to 21.57 million shares) - Vanke (02202): 12.63% (from 268 million shares to 279 million shares) - Ping An Insurance (02318): 12.59% (from 959 million shares to 938 million shares) - Zijin Mining (02899): 12.58% (from 750 million shares to 754 million shares) - MicroPort Medical (00853): 11.10% (from 213 million shares to 212 million shares) - Hansoh Pharmaceutical (01276): 11.01% (from 28.01 million shares to 28.43 million shares) - Fuyao Glass (06865): 10.85% (from 49.22 million shares to 47.94 million shares) [2] - **Top 10 Companies with Increased Short Positions** - Ganfeng Lithium (01772): Increased by 1.20% (from 14.05% to 15.25%) - Minmetals Resources (01208): Increased by 0.96% (from 1.96% to 2.93%) - Yuexiu Transport Infrastructure (01052): Increased by 0.76% (from 1.08% to 1.84%) - Jinli Permanent Magnet (06680): Increased by 0.66% (from 7.76% to 8.42%) - China Civil Aviation Information Network (00696): Increased by 0.58% (from 6.63% to 7.21%) [2] - **Top 10 Companies with Decreased Short Positions** - GCL-Poly Energy (03800): Decreased by 3.16% (from 11.76% to 8.59%) - Dongfang Electric (01072): Decreased by 2.03% (from 6.78% to 4.75%) - Jinxin Fertility (01951): Decreased by 0.76% (from 10.61% to 9.85%) - Yangtze Optical Fibre and Cable (06869): Decreased by 0.75% (from 7.03% to 6.28%) - Shanghai Electric (02727): Decreased by 0.72% (from 2.25% to 1.52%) [3][4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總 ...

消息面上，微创医疗宣布重组心律管理业务，附属微创心通拟合并CRM Cayman。有市场人士指出，此 次合并意在化解心律业务"达标上市"对赌压力。摩通大根表示，交易顺利完成，有助消除持续困扰公司 的重大不明朗因素。此外，公司此前引入国企背景的上海实业作为战略股东。国泰海通证券表示，上实 资本依托其国资背景和产业资源，有望助力集团核心业务拓展及潜在战略并购，追求更卓越的公司治理 水平，为集团持续创新、高质量发展及规模能级提升提供支持。 微创医疗(00853)尾盘再涨5%，截至发稿，涨5.1%，报16.08港元，成交额2.67亿港元。 ...

智通财经APP获悉，微创医疗(00853)尾盘再涨5%，截至发稿，涨5.1%，报16.08港元，成交额2.67亿港 元。 消息面上，微创医疗宣布重组心律管理业务，附属微创心通拟合并CRM Cayman。有市场人士指出，此 次合并意在化解心律业务"达标上市"对赌压力。摩通大根表示，交易顺利完成，有助消除持续困扰公司 的重大不明朗因素。此外，公司此前引入国企背景的上海实业作为战略股东。国泰海通证券表示，上实 资本依托其国资背景和产业资源，有望助力集团核心业务拓展及潜在战略并购，追求更卓越的公司治理 水平，为集团持续创新、高质量发展及规模能级提升提供支持。 ...

Core Viewpoint - MicroPort Medical (00853) has seen a nearly 5% increase in stock price, currently trading at 15 HKD, with a transaction volume of 86.87 million HKD, following the announcement of a restructuring in its cardiac rhythm management business [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary post-merger [1] - The merger aims to alleviate the pressure of meeting the "listing target" for the cardiac rhythm business, as noted by market analysts [1] Group 2: Market Reactions and Analyst Insights - JPMorgan expressed that the successful completion of the transaction would help eliminate significant uncertainties that have been troubling the company [1] - Bank of America Securities highlighted the strategic partnership with Shanghai Industrial, a state-owned enterprise, which is expected to support the company's financial and business development [1] Group 3: Future Profitability and Growth - The bank anticipates that through cost control and the disposal of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1]

Core Viewpoint - MicroPort Medical (00853) has seen a nearly 5% increase in stock price, currently trading at 15 HKD, with a transaction volume of 86.87 million HKD. The company announced a restructuring of its cardiac rhythm management business, which is expected to alleviate pressure related to the "listing performance" gamble [1]. Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary post-merger [1]. - The merger is aimed at resolving uncertainties that have been a significant concern for the company [1]. Group 2: Market Analysis - JPMorgan has indicated that the successful completion of the transaction will help eliminate major uncertainties that have been affecting the company [1]. - Bank of America Securities has noted that the introduction of a state-owned enterprise, Shanghai Industrial, as a strategic shareholder will support the company's financial and business development [1]. Group 3: Financial Outlook - The bank anticipates that through cost control and the disposal of non-core assets, the company could achieve profitability by the first half of 2026 [1]. - Rapid growth in overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1].

Core Viewpoint - MicroPort Medical (00853) is restructuring its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to support the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]

Core Viewpoint - MicroPort Medical (00853) is restructuring its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical announced the merger of its subsidiary MicroPort Cardiac Rhythm Management (CRM) with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to support the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - The rapid growth of overseas business is expected to diversify domestic market risks and provide long-term growth visibility [1]

Core Viewpoint - MicroPort Medical (00853) has announced a restructuring of its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to bolster the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]